Peer-Reviewed Publications & Presentations
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
Highlights:
•EloLenDex is associated with 4-year PFS of 89% in patients with high-risk SMM
•Immune reactivity, post-therapy immune normalization are associated with longer PFS
•Higher abundance of GZMK+ cytotoxic T cells is associated with longer PFS
•Blood-based immune profiling detects immune dysregulation associated with disease
Whole genome sequencing of multiple myeloma genomes with a novel clinical assay enables identification of genetic alterations underlying immunotherapy resistance — AACR 2026
Presented at AACR; demonstrates GenoPredicta’s whole-genome sequencing from as few as ~50 circulating tumor cells, with 100% concordance to bone marrow and FISH and detection of subclonal, resistance-associated alterations from blood.
MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology
The foundational study establishing whole-genome sequencing of intact circulating tumor cells from peripheral blood as a clinically viable approach to comprehensive myeloma characterization – including at minimal disease burden.
Predicta Newsletter
Enter your email address to subscribe.
Enter Email Address:
Predicta Biosciences
750 Main Street, Lab 413
Cambridge, MA 02139